ALPHA-SYNUCLEIN E46K

The A53T mutation in alpha-synuclein is a well-established cause of familial Parkinson's disease, officially classified as pathogenic by ClinVar based on evidence from multiple expert submitters. Its complete absence from the gnomAD population database—representing hundreds of thousands of healthy individuals—strongly supports that this mutation is not a benign variant but a genuine disease driver. Patients carrying A53T typically develop Parkinson's symptoms at younger ages than sporadic cases, experiencing the characteristic tremor, rigidity, and movement difficulties as dopamine-producing neurons die in the brain's substantia nigra region. This computational structure prediction achieved a moderate average confidence score of 60.9 pLDDT, meaning substantial portions of the protein structure remain uncertain. Alpha-synuclein is an intrinsically disordered protein—it lacks a stable folded shape under normal conditions—which makes it particularly challenging for prediction algorithms like AlphaFold2 to model accurately. The low-to-moderate confidence across most regions indicates we should interpret structural details cautiously, as the true atomic arrangement may differ significantly from this prediction. However, even partial structural information can provide insights into how the A53T mutation might alter the protein's behavior. The A53T mutation replaces alanine (a small, hydrophobic amino acid) with threonine (which carries a polar hydroxyl group) at position 53. Research has shown this single change dramatically increases alpha-synuclein's tendency to aggregate into toxic forms. The mutant protein forms oligomers and protofibrils—small clumps that punch holes in cellular membranes—more readily than normal alpha-synuclein, and these structures show enhanced ability to seed further aggregation in a prion-like manner [1]. Studies demonstrate that A53T alters the protein's secondary structure near the mutation site and in flanking regions (residues 60-70 and 80-90), though these changes are more localized compared to other Parkinson's mutations. The mutation also increases alpha-synuclein secretion from neurons and promotes the formation of annular and tubular protofibrils that destabilize mitochondrial and cellular membranes, ultimately leading to neuronal death. Beyond direct effects on protein structure, A53T triggers a cascade of cellular dysfunction. The mutant protein impairs mitochondria—the cell's energy factories—reducing their movement along neuronal processes and disrupting energy production. Research using modified alphaB-crystallin has shown potential for preventing A53T fibrillization, suggesting therapeutic strategies targeting the aggregation process itself [1]. The mutation also amplifies neuroinflammation, with studies demonstrating that microglia (brain immune cells) carrying A53T show intrinsic proinflammatory activation and increased oxidative stress, creating a toxic environment that accelerates neurodegeneration even in early disease stages. The moderate confidence scores in this structural prediction limit our ability to pinpoint exactly which structural features drive A53T's pathogenic effects. Low-confidence regions may include functionally important areas where the mutation exerts its influence, but we cannot reliably compare these predictions to experimental structures without higher-quality models. The clinical evidence, however, is unambiguous: A53T is a fully penetrant pathogenic mutation that invariably causes Parkinson's disease in carriers, making it a critical target for understanding disease mechanisms and developing therapies that could prevent or slow neurodegeneration in affected families.